Xaliproden (** Investigational compound (no approved brand names - development discontinued) **)
Other Medications
Description
Xaliproden (also known as SR57746A) was an investigational drug studied in clinical trials, specifically in combination with standard chemotherapy (5-Fluorouracil, Leucovorin, and Oxaliplatin) for colorectal cancer. The main goal of the trials was to see if Xaliproden could help prevent or reduce the nerve damage (neurotoxicity), particularly peripheral sensory neuropathy, that can be caused by oxaliplatin. Researchers also wanted to ensure that adding Xaliproden did not negatively impact the effectiveness of the chemotherapy in treating the cancer itself. The trials assessed various aspects of nerve function, safety, and the drug's effect on tumor progression and survival. Development of this drug has been discontinued.
Mechanism of Action
Xaliproden was being investigated for its potential to reduce oxaliplatin-induced peripheral neuropathy. The specific mechanism by which it was thought to work is not fully detailed in the available information, but it was intended to be used alongside standard chemotherapy regimens containing oxaliplatin.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.